Hypopharyngeal Carcinoma Clinical Trial
Official title:
Neck Dissection Versus Radiotherapy for Cervical Lymph Node Metastasis in Advanced Hypopharyngeal Carcinoma With Poor Response to Induction Chemotherapy : A Randomized Controlled Prospective Study
At the time of diagnosis, approximately 60%-80% of patients with hypopharyngeal cancer are found with cervical lymph node metastasis. Cervical nodal metastasis is an important prognostic factor in hypopharyngeal cancer. Induction chemotherapy is frequently used in advanced hypopharynx cancer. However, sometimes CR was obtained at the tumor's primary site but not in the palpable lymph nodes in the neck, the large cervical lymph node metastasis poorly responded to induction chemotherapy in a considerable percentage of patients. At present, patients with primary tumor achieved CR preferred to receive definitive radiotherapy no matter cervical lymph node metastasis SD or progression. But, radiotherapy was poor effective to the big cervical lymph node metastasis, because the inner of big cervical lymph node metastasis was hypoxic and necrosis. The investigators conducted a prospective, randomised trial to compare neck dissection with definitive radiotherapy for advanced hypopharyngeal cancer cervical lymph node metastasis with poor response to induction chemotherapy.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | January 1, 2028 |
Est. primary completion date | January 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document 2. Age= 18 and= 75 years 3. Histological/ cytological/ Imaging examination proven hypopharyngeal squamous-cell carcinoma in preoperative assessment 4. Advanced hypopharyngeal cancer with metastatic cervical lymph node more than 2cm in diameter 5. EPOG=1,KPS= 70 6. No contraindication of surgery and radiotherapy 7. No serious disease history of the heart, liver, kidney, lung and other important organs 8. Expected survival period= 12 months 9. Good compliance Exclusion Criteria: 1. Inability to provide an informed consent 2. Other malignancy tumor history,(except for cured skin basal cell carcinoma and papillary thyroid carcinoma) 3. Serious cardiovascular, liver, respiratory, kidney and neurologic and psychiatric disease with clinical symptoms 4. The patient has received prior surgery or radiotherapy (except for biopsy) 5. The patient has received chemotherapy or immunotherapy 6. Pregnant or lactating women 7. Other disease requiring simultaneous surgery or radiotherapy |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital | Tianjin Medical University General Hospital, Tianjin Medical University Second Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neck control rates | The percentage of patients without cervical lymph node metastasis | 2 years | |
Secondary | Disease-free survival | The proportion of patients did not find clear evidence of recurrence or metastasis | 1 year | |
Secondary | Disease-free survival | The proportion of patients did not find clear evidence of recurrence or metastasis | 2 years | |
Secondary | Disease-free survival | The proportion of patients did not find clear evidence of recurrence or metastasis | 3 years | |
Secondary | Disease-free survival | The proportion of patients did not find clear evidence of recurrence or metastasis | 5 years | |
Secondary | Overall survival | The proportion of patients who survived | 3 years | |
Secondary | Overall survival | The proportion of patients who survived | 5 years | |
Secondary | Quality of life(QOL) QLQ-C30 | Evaluated by the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 | 1 year | |
Secondary | Quality of life(QOL) QLQ-HN35 | Evaluated by the European Organization for Research and Treatment of Cancer(EORTC) QLQ-HN35 | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05494190 -
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
|
N/A | |
Active, not recruiting |
NCT04156698 -
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT04788264 -
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment
|
N/A | |
Completed |
NCT03132727 -
Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer
|
||
Recruiting |
NCT05075980 -
HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers
|
Phase 2 | |
Terminated |
NCT02062632 -
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
|
Phase 2 |